Grace Therapeutics
GRCE
33 hedge funds and large institutions have $12.6M invested in Grace Therapeutics in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
88% more capital invested
Capital invested by funds: $6.67M → $12.6M (+$5.88M)
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
22% more funds holding
Funds holding: 27 → 33 (+6)
0.04% more ownership
Funds ownership: 0.09% → 0.13% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.28M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$568K |
| 3 |
Renaissance Technologies
New York
|
+$452K |
| 4 |
Morgan Stanley
New York
|
+$346K |
| 5 |
Barclays
London,
United Kingdom
|
+$206K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFS
Monetta Financial Services
Wheaton,
Illinois
|
-$189K |
| 2 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$95K |
| 3 |
BCM
Bayesian Capital Management
Brooklyn,
New York
|
-$46K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$41K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$30.8K |
GRCE Hedge Fund Activity: Q4 2019 in Review
33 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2019, worth a combined $12.6M — up 88% from $6.67M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GRCE positions and 9 closed out — a net gain of 6 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $1.28M. The largest seller was Monetta Financial Services, exiting entirely with an estimated $189K sold.
- 33 institutional investors held Grace Therapeutics (GRCE) as of Q4 2019, up from 27 in Q3 2019.
- Funds reported $12.6M of Grace Therapeutics stock for Q4 2019, up 88% quarter-over-quarter.
- 15 funds opened new Grace Therapeutics positions in Q4 2019 and 9 closed out, a net change of +6 holders.
- The largest Grace Therapeutics buyer in Q4 2019 was Acuta Capital Partners, an estimated $1.28M added.
- The largest Grace Therapeutics seller in Q4 2019 was Monetta Financial Services, an estimated $189K sold.
Based on aggregated 13F filings for Q4 2019.